University of Cambridge

NovalGen appoints Dr Michael Owen and Mr Scott Clark to the Board of Directors

Retrieved on: 
Monday, January 9, 2023

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.

Key Points: 
  • LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, alongside a disruptive auto-regulation platform, today announces the appointment of Dr Michael Owen and Mr Scott Clark as Non-Executive Directors to its Board, effective January 2023.
  • Dr Owen is also an advisor to several Venture Capital LPs and is Chairman of Avacta plc’s SABs.
  • Prior to board services, Dr Owen co-founded and served as the first CSO of Kymab Ltd, a biopharmaceutical company recently acquired by Sanofi.
  • Prior to Tizona, Mr Clark was the Global Head of Oncology Partnering and Head of Asia and Emerging Markets Partnering at Roche.

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

Retrieved on: 
Monday, January 9, 2023

“We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said Mr. Zeeshan Saeed, President of FSD Pharma.

Key Points: 
  • “We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said Mr. Zeeshan Saeed, President of FSD Pharma.
  • “Australia is a hotbed for clinical stage biotech companies, and our drug development programs will be able to take advantage of facilities offered by various government incentives in Australia,” added Mr. Saeed.
  • Chataway, Dhanda and Lê have agreed to join our international panel to contribute to our current and new programs,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma.
  • Dr. Chataway received his Bachelor of Medicine & Surgery from Oxford University, and Doctor of Philosophy from Cambridge University.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

STORM Therapeutics Expands R&D Leadership Team

Retrieved on: 
Tuesday, January 10, 2023

Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.

Key Points: 
  • Matthew will work with the leadership team to progress STORM's pipeline while working with functional heads and project leaders to define medicinal chemistry, drug discovery, DMPK, PK–PD, CMC and preclinical development strategies.
  • Newly promoted Vice President of Medicinal Chemistry, Beth Thomas has over 20 years of experience in medicinal and computational chemistry and joined STORM Therapeutics in 2016.
  • Oliver Rausch, Chief Scientific Officer of STORM Therapeutics, said: "I am delighted to welcome Matthew to the leadership team at STORM.
  • Matthew Fyfe, Senior Vice President of STORM Therapeutics, commented: "I am excited to be joining this strong and experienced drug discovery and development team.

NGD and CEO Paul Rhodes Announce Publication in mSphere

Retrieved on: 
Monday, January 9, 2023

CAMBRIDGE, United Kingdom, Jan. 9, 2023 /PRNewswire-PRWeb/ -- Next Gen Diagnostics announces the publication in mSphere of a study validating the accuracy of its fully automated bioinformatics platform for the detection of transmission of infection. Titled "Large-scale evaluation of a rapid fully automated analysis platform to detect and refute outbreaks based on MRSA genome comparisons" and led by University of Cambridge Professor and NGD Scientific Advisory Board member Sharon Peacock, the study compared the detection of transmission clusters by the gold standard manual bioinformatics pipeline developed by the Peacock group for previous seminal publications on hospital transmission with the automated NGD system. Analyzing 3,311 case pairs, the paper reports that both the manual bioinformatics system and the NGD automated pipeline identified the same 66 transmission clusters. The authors concluded "…that [NGD's] automated transmission detection tool worked at least as well as a researcher-led manual analysis and indicates how such tools could support the rapid use of MRSA genomic epidemiology in infection control practice."

Key Points: 
  • Analyzing 3,311 case pairs, the paper reports that both the manual bioinformatics system and the NGD automated pipeline identified the same 66 transmission clusters.
  • "We have seen our system enable the power of prospective sequencing to detect transmission and guide intervention to stop outbreaks," noted Paul A. Rhodes, Ph.D., Next Gen Diagnostics CEO.
  • "Now with this new publication from Professor Peacock's group the accuracy of the NGD automated bioinformatics system's computation of SNP-level relatedness between infections has been quantitatively validated.
  • "We knew that a rigorous quantification of the accuracy of the NGD automated bioinformatics system was a key prerequisite for its consideration in clinical use," said Professor Peacock, NGD Scientific Advisory Board member.

Long Ridge Equity Partners Announces Three Promotions

Retrieved on: 
Wednesday, January 4, 2023

Long Ridge Equity Partners (“Long Ridge”), a private equity firm focused on the financial and business technology sectors, today announced the promotions of Andrew Cedar and Jason Melton to Partner, and Doug Nelson to Principal.

Key Points: 
  • Long Ridge Equity Partners (“Long Ridge”), a private equity firm focused on the financial and business technology sectors, today announced the promotions of Andrew Cedar and Jason Melton to Partner, and Doug Nelson to Principal.
  • All three promotions support the continued growth of Long Ridge and the firm’s organic approach to team-building: recruiting top junior talent and developing/promoting from within.
  • “These promotions represent the well-deserved recognition of these individuals, who have been instrumental to Long Ridge’s growth and success,” said Jim Brown, Founder and Managing Partner at Long Ridge.
  • Prior to Long Ridge, Andrew was at McKinsey & Company, where he reported directly to the Global Managing Partner.

VinFuture Announces the Event Series of VinFuture Sci-Tech Week 2022

Retrieved on: 
Wednesday, December 14, 2022

Hanoi, Vietnam--(Newsfile Corp. - December 13, 2022) - VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17-21, 2022 in Hanoi.

Key Points: 
  • Hanoi, Vietnam--(Newsfile Corp. - December 13, 2022) - VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17-21, 2022 in Hanoi.
  • Taking place over five days, the event series includes: "Conversation with the VinFuture Prize Council and Pre-screening Committee"; "Innovate Today, Create Tomorrow" Inspirational Talk Series; "Science for Life Symposium"; "VinFuture Prize Award Ceremony"; and "Talk Future: A dialogue with the 2022 VinFuture Prize Laureates".
  • The main event of the week is the 2022 VinFuture Prize Award Ceremony - Reviving and Reshaping - held in the evening of December 20, 2022, at the Hanoi Opera House to honor the next VinFuture laureates.
  • Closing the VinFuture Sci-Tech Week is Talk Future: A dialogue with the 2022 VinFuture Prize Laureates, which will take place throughout the day on December 21, 2022.

Vingroup: VinFuture announces the event series of VinFuture Sci-Tech Week 2022

Retrieved on: 
Sunday, December 18, 2022

HA NOI, VIETNAM - Media OutReach - 13 December 2022 – VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17–21, 2022 in Hanoi.

Key Points: 
  • HA NOI, VIETNAM - Media OutReach - 13 December 2022 – VinFuture Foundation officially announces the agenda of the second VinFuture Sci-Tech Week, taking place between December 17–21, 2022 in Hanoi.
  • Taking place over five days, the event series includes: “Conversation with the VinFuture Prize Council and Pre-screening Committee”; “Innovate Today, Create Tomorrow” Inspirational Talk Series; “Science for Life Symposium”; “VinFuture Prize Award Ceremony”; and “Talk Future: A dialogue with the 2022 VinFuture Prize Laureates”.
  • The main event of the week is the 2022 VinFuture Prize Award Ceremony – Reviving and Reshaping – held in the evening of December 20, 2022, at the Hanoi Opera House to honor the next VinFuture laureates.
  • Closing the VinFuture Sci-Tech Week is Talk Future: A dialogue with the 2022 VinFuture Prize Laureates, which will take place throughout the day on December 21, 2022.

Leading Global Property Firm, Savills, Provides Initial Funding for Master’s-Level Study Abroad Initiative for Queens College Graduates to Attend Cambridge University’s Lucy Cavendish College

Retrieved on: 
Saturday, December 17, 2022

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Both Queens College and Lucy Cavendish College are committed to serving exceptional students from underrepresented, low-income, and often marginalized communities.
  • “As a global leader in commercial real estate, we are excited to support this amazing international initiative with Cambridge University’s Lucy Cavendish College that will help to bring a remarkable Queens College graduate to study in the UK,” concluded Schuman.
  • Lucy Cavendish College is the fastest growing and most diverse of the 31 constituent colleges within the University of Cambridge in the United Kingdom.
  • Founded in 1965, the College is named in honor of Lucy Cavendish, a leading 19th century activist for the reform of women's education.

Cambridge GaN Devices and IFP Energies nouvelles Sign Automotive Inverter Development Deal

Retrieved on: 
Tuesday, December 13, 2022

Cambridge GaN Devices (CGD) , the fabless, clean-tech semiconductor company that develops a range of energy-efficient GaN-based power devices to make greener electronics possible, has signed an agreement with IFP Energies nouvelles (IFPEN) , a major French public research and training organization in the fields of energy, transport and the environment, to develop an innovative automotive inverter using advanced GaN devices.

Key Points: 
  • Cambridge GaN Devices (CGD) , the fabless, clean-tech semiconductor company that develops a range of energy-efficient GaN-based power devices to make greener electronics possible, has signed an agreement with IFP Energies nouvelles (IFPEN) , a major French public research and training organization in the fields of energy, transport and the environment, to develop an innovative automotive inverter using advanced GaN devices.
  • Therefore we are particularly excited that IFPEN has chosen CGDs ICeGaN GaN HEMTs in this new automotive inverter design.
  • Cambridge GaN Devices (CGD) is a fabless semiconductor company spun-out by Professor Florin Udrea and Dr Giorgia Longobardi from Cambridge University in 2016 to exploit a revolutionary technology in power devices.
  • IFP Energies nouvelles (IFPEN) is a major research and training player in the fields of energy, transport and the environment.